The Isotope Production Map
Q3 2026 edition
Every producer, route and capacity tier in medical isotope supply. 79 radionuclides assessed, 94 countries, 272 organisations and facilities, every material fact traced to a dated source. This is the reference map of who makes the isotopes that nuclear medicine runs on, where, by which route, and at what stage. It is built for the people who have to act on it: Heads of Supply and CMC choosing between producers, producers watching entrants, investors separating announced capacity from irradiated capacity, and agencies that need the global picture with sources they can check.
Who reads this
Read by isotope production, radiopharma supply chain, and institutional investor teams across the US, UK, Canada, and EU.
Built from the primary record, checked natively in eleven languages, and set against what the practice sees directly through retained search across the radiopharmaceutical supply chain.
Authored by
Byron Fitzgerald, Founder, ProGen Search
A rebuild, not a refresh
The Q3 2026 edition was rebuilt from scratch. Every claim in the previous edition was independently re-derived, corrected or dropped: of 69 items assessed, 33 were re-derived, 17 partially held, five were contradicted and 14 were removed. Nothing was carried forward on the old edition's authority. The corrections are published in the edition itself and in the free Executive Brief, so you can see exactly what changed and why.
Searched in eleven languages. Beyond English, the producer record was checked natively in Korean, Japanese, Simplified Chinese, Russian, German, French, Dutch, Brazilian Portuguese, Spanish, Polish and Turkish, covering the national regulators, research institutes, government registries, nuclear agencies and company sites of those languages' principal producing geographies. That is how this edition carries KHNP's Wolsong Lu-177 programme, Korea's Tb-161 work, the correction that RA-10 in Argentina has not gone critical, and the correction placing Russia's isotope expansion at Leningrad rather than Kursk. Every one of those errors sat in English-language sources. Every correction came from the country's own language.
How capacity is written. Every producer table distinguishes four tiers: announced, commissioned, GMP-qualified and actual output. Where a tier is not public the table says “not disclosed”. No figure is estimated, converted between incompatible units, or moved from one tier to another. Announced capacity is reversible. Irradiated capacity is not. Most of what gets called supply is still the first kind.
How it was checked. Every material statement traces to a dated source record carrying the source, its publication date, the date it was retrieved and a source tier. Primary and regulatory sources first, then peer-reviewed literature, then company material; trade press is never load-bearing on its own. Before publication the findings went through four rounds of structured adversarial review, conducted separately from the research and tasked with breaking them.
Buy this report
From
$1,495
Three licence tiers for individuals, teams, and institutions.
Individual
Single reader
$1,495
Enterprise
One organisation, all sites
$5,995
Investor & Bank Licence
Banks and institutional investors
$14,995
Chapters
The state of isotope supply: five clusters, one outlook
The synthesis. Five clusters where supply risk concentrates: the actinium bottleneck, the Mo-99 succession gap, single-chain and monopoly positions, enrichment and target supply, and Class 7 logistics. The 2027 to 2030 outlook, a headline supply verdict for every radionuclide covered, and the eight open questions that matter most to a buyer's own diligence.
Mo-99 / Tc-99m: the technetium generator chain
The irradiator set at the centre of Western supply, unchanged since 2023. PALLAS at 2032, JHR at 2034, RA-10 not yet critical, KJRR targeting criticality end-2027. Europe's target manufacture and its dependence on a depleting US-held stockpile. The January 2026 transfer of the TechneLite generator brand, and what it means that no new Western high-flux research reactor enters service before 2032 on current schedules.
Lutetium-177
The carrier-added and non-carrier-added routes, producer by producer, with the Yb-176 precursor chain underneath them. Reactor irradiation slots, processing capacity, the power-reactor entrants, and the de-Russification of precursor supply now under contract.
Terbium-161
The Gd-160 reactor route in full, with the complete producer table: who irradiates, who processes, who is GMP-qualified, and who has actually shipped. The competition for high-flux irradiation slots against Lu-177, and the enriched Gd-160 precursor chapter that sits beneath it.
The alpha emitters: Ac-225, Ra-223, Ra-224, Pb-212, At-211, Th-227
The Ac-225 arithmetic across all five routes and every named producer, with what each has actually irradiated. The single Ac-227 chain behind Ra-223. The one Norwegian plant supplying Th-228 to five independent developers. The accelerator entrants and the Ra-226 feedstock question no public source can answer.
Beta emitters: the rest of the field
Y-90, I-131, Sm-153, Sr-89, Re-186 and Re-188, Cu-67, Ho-166 and the radiosynovectomy isotopes. Producer tables, routes and, where the public record cannot carry a current verdict, a statement that it cannot.
Diagnostics: PET, generator and legacy imaging isotopes
F-18, Ga-68 and Ge-68, Cu-64, Zr-89, I-123 and I-124, the scandium isotopes, and the cardiac and legacy imaging chain. Why short half-lives force decentralised networks, and where the generator supply behind them actually sits.
The supply base: producer classes across the isotope map
Research reactors, power reactors, cyclotrons and accelerators, generator manufacture, processing, enrichment and target fabrication. The four-stage model, and the one capability the public record cannot map at all: who fabricates enriched material into qualified irradiation targets.
The regional production landscape
Every producing geography, chapter by chapter, including the Asia-Pacific and Eastern European coverage that native-language research materially changed. Pakistan and Kazakhstan enter the map for the first time, each on two independent sources at regulatory or peer-reviewed tier.
Coverage boundaries and confidence
Exactly what was and was not searched, registry by registry, with the structural limit of each one stated. The 94-country matrix and its three statuses. The four isotopes tested and excluded by name, and why. The languages searched, and the limit that carries for the languages that were not.
Annex: sealed-source brachytherapy isotopes
A bounded annex under its own scope statement, covering the sealed-source isotopes and the fabricators behind them.
Appendix: organisations and facilities
Every organisation and named production facility appearing in the edition, with country and production route. 272 organisations, 292 rows.
Free Preview
Read the Executive Brief first.
Free, and enough to judge the edition on. The supply verdict for every radionuclide profiled, the corrections to the previous edition, the coverage by country, the five fragility clusters, and one complete producer table so you can see the depth for yourself.
No spam, no resale.
From the report
50 to 70 Ci
a year is the ceiling on the only Ac-225 route with a long clinical supply record. The demand estimate published by one of the companies building the alternative is 500 to 800.
A Phase 3 was paused in 2024 citing Ac-225 supply. Two sponsors have each contracted four or more independent producers. That is not diversification. That is rationing with paperwork.
Who reads this and what they use it for
Heads of Supply, CMC and Technical Operations
Radiopharma developers who need to know which of their isotopes runs through a single building with no named backup, and which producers can actually deliver against an announced figure.
Producers, enrichers and CDMOs
Isotope producers and contract manufacturers watching entrants and competitor announcements, including the ones that appeared only in Korean, Japanese or Russian.
Investors and corporate development
Investors with radiopharma holdings who need announced capacity separated from irradiated capacity before it is priced as the same thing.
Agencies, national laboratories and institutes
Government agencies and research institutes needing the global picture with sources they can check, including the country-level coverage matrix and its stated boundaries.
Byron Fitzgerald, Founder, ProGen Search
About the Author
Byron Fitzgerald
Byron Fitzgerald has spent more than 15 years in life sciences executive search and founded ProGen Search in 2024. He is a three-time founder, having previously bootstrapped a specialist consultancy from a standing start to 36 consultants. He has placed VP to C-suite leadership across Quality, MSAT, Technical Operations, CMC, Manufacturing, Regulatory, and Business Development functions for organisations ranging from pre-clinical biotechs to multinational CDMOs and radiopharma developers. Through retained search and commissioned intelligence work, he speaks daily with the C-suite, investors, PE/VC partners, and BD leaders who set strategy across this sector.
His published market intelligence on radiopharmaceutical manufacturing, CDMO capacity constraints, ADC execution risk, and advanced modality talent markets is read by C-suite leaders, institutional investors, and board members globally.
Choose your access
Three tiers, calibrated to how you intend to use the work.
Launch pricing
launch pricing ends
Code LAUNCH20 takes 20 percent off any licence at checkout until then. Standard pricing applies thereafter.
Individual
$1,495
Single reader. Personal use within one company.
- Single named reader licence
- Full PDF edition (244 pages, 65 tables)
- Source attribution for internal slide decks and memos: "Source: ProGen Search Limited" or "Source: ProGen Search"
- Direct email access to Byron Fitzgerald for clarification questions
Enterprise
$5,995
Unlimited users across one organisation and all of its sites. The right licence for an institute, an agency or a producer.
- Full organisation licence covering all employees, all sites and majority-owned subsidiaries
- Full PDF edition (244 pages, 65 tables)
- Internal redistribution rights (intranet, shared drives, internal presentations, board packs)
- Source attribution required when used in client-facing or external materials: "Source: ProGen Search Limited" or "Source: ProGen Search"
- Priority email access to Byron Fitzgerald
- Invoiceable against a purchase order
Need to pay by invoice or PO? Email byron.fitzgerald@progensearch.com.
Investor & Bank Licence
$14,995
Investment banks, institutional investors, and consulting firms citing the edition in client materials.
- Full firm licence covering all investment professionals, analysts, and portfolio companies
- Full PDF edition (244 pages, 65 tables)
- Use in investor memos, client deliverables, due diligence reports, and committee papers
- Source attribution required: "Source: ProGen Search Limited" or "Source: ProGen Search"
- Priority email access to Byron Fitzgerald
Need to pay by invoice or PO? Email byron.fitzgerald@progensearch.com.
By completing your purchase, you agree to our Purchase Terms.
Frequently asked questions
What changed between the previous edition and this one?
Everything was re-derived. The previous edition ran to 56 pages and was dated April 2026. This one runs to 244 pages and was finalised on 2 September 2026 with a data cut-off of 31 August 2026. Of 69 items carried into the verification pass, 33 were re-derived, 17 partially held, five were contradicted and 14 were dropped. Nothing was carried forward on the old edition's authority. The corrections are listed in the free Executive Brief.
How is capacity presented?
On four tiers, in every producer table: announced, commissioned, GMP-qualified, and actual output. Where a tier is not publicly disclosed the table says "not disclosed" rather than estimating. That is deliberate. In this industry actual production and shipment volumes are frequently not public, and "not disclosed" is a finding about the producer rather than a gap in the research.
Are the data points sourced?
Yes. Every material figure and named fact carries inline attribution naming the source and its date. The source base runs from primary and regulatory material first (regulators, registries, government budget documents, securities filings), then peer-reviewed literature, then company primary material. Trade press and aggregators are used only as pointers and are never load-bearing on their own.
How current is it, and is there an update entitlement?
Data cut-off is 31 August 2026. Each edition is a standalone purchase, issued as a complete dated document, with no interim updates and no refresh entitlement. The map is refreshed as the landscape moves rather than on a fixed calendar, because production capacity in this industry changes by commissioning event, licence grant and transaction, not by quarter.
How is this different from State of Radiopharmaceuticals 2026?
State of Radiopharmaceuticals maps the clinical and commercial landscape: which drugs are in development, who owns them, and where the capital is flowing. The Isotope Production Map sits one layer beneath that. It maps the physical infrastructure that has to deliver the atoms before any of those drugs reaches a patient, producer by producer and route by route. Read together they give you the full picture from molecule to manufacturing.
Can I share this with my team or board?
The Individual Licence covers a single named reader. The Enterprise Licence covers your whole organisation and all of its sites, including internal sharing on intranets and in internal presentations. The Investor & Bank Licence extends that scope to your portfolio companies and clients. See the Purchase Terms for the precise scope of each tier.
How is the edition delivered?
Personally, within one business day of purchase. The edition is a 244-page document and is sent as a private download link rather than an attachment.
Free Radiopharma intelligence
Read Radiopharma CDMO & Supply Chain Report 2025 and The Radiopharmaceutical Blueprint in the Intelligence Vault. Visit Vault →
Ready when you are.
If your team is making radiopharma capital, sourcing or strategy decisions this year, the isotope supply base is where the binding constraints live. Supply meets demand today, on an ageing base that is not being renewed. That sentence is fine until the day it is not.
View pricingWant ongoing intelligence between flagship reports? ProGen Radar Pro - $99/month, 14-day guarantee. Learn more →